Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 8, 2015, 59 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.90 to $2,613,411,881.91.

Highlighted Stocks Traded by Insiders:

KMG Chemicals (KMG) - FREE Research Report

Hatcher David L, who is 10% Owner at KMG Chemicals, sold 1,500 shares at $29.90 on April 8, 2015. Following this transaction, the 10% Owner owned 2.0 million shares meaning that the stake was reduced by 0.07% with the 1,500-share transaction.

The shares most recently traded at $29.87, down $0.03, or 0.1% since the insider transaction. Historical insider transactions for KMG Chemicals go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 5,000

The average volume for KMG Chemicals has been 37,400 shares per day over the past 30 days. KMG Chemicals has a market cap of $346.1 million and is part of the basic materials sector and chemicals industry. Shares are up 49.45% year-to-date as of the close of trading on Wednesday.

KMG Chemicals, Inc., through its subsidiaries, engages in the manufacture, formulation, and distribution of specialty chemicals in the United States, Mexico, Canada, Europe, Israel, and Singapore. It operates in two segments, Electronic Chemicals and Wood Treating Chemicals. The stock currently has a dividend yield of 0.4%. The company has a P/E ratio of 49.4. Currently, there is 1 analyst who rates KMG Chemicals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMG - FREE

TheStreet Quant Ratings rates KMG Chemicals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full KMG Chemicals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CoreSite Realty (COR) - FREE Research Report

Finnin Jeffrey S, who is CFO and Treasurer at CoreSite Realty, sold 1,451 shares at $50.72 on April 8, 2015. Following this transaction, the CFO and Treasurer owned 107,409 shares meaning that the stake was reduced by 1.33% with the 1,451-share transaction.

The shares most recently traded at $50.23, down $0.49, or 0.98% since the insider transaction. Historical insider transactions for CoreSite Realty go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 6,615
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 20,262
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 20,262

The average volume for CoreSite Realty has been 157,100 shares per day over the past 30 days. CoreSite Realty has a market cap of $1.1 billion and is part of the financial sector and real estate industry. Shares are up 28.91% year-to-date as of the close of trading on Wednesday.

CoreSite Realty Corporation engages in the ownership, acquisition, construction, and management of data centers. The stock currently has a dividend yield of 3.43%. The company has a P/E ratio of 74.3. Currently, there are 4 analysts who rate CoreSite Realty a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COR - FREE

TheStreet Quant Ratings rates CoreSite Realty as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, solid stock price performance, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full CoreSite Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NuVasive (NUVA) - FREE Research Report

Blackford Quentin S., who is CFO and CAO at NuVasive, sold 5,000 shares at $36.30 on April 8, 2015. Following this transaction, the CFO and CAO owned 12,902 shares meaning that the stake was reduced by 27.93% with the 5,000-share transaction.

The shares most recently traded at $43.75, up $7.45, or 17.02% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 3,615
  • 12-Week # shares sold: 26,893
  • 24-Week # shares sold: 42,578

The average volume for NuVasive has been 507,000 shares per day over the past 30 days. NuVasive has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are down 8.74% year-to-date as of the close of trading on Wednesday.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. Currently, there are 11 analysts who rate NuVasive a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full NuVasive Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null